| Bioactivity | ZLN005 is a potent activator of peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α)[1]. | ||||||||||||
| Target | Peroxisome proliferator-activated receptor-γ coactivator-1α | ||||||||||||
| Invitro | ZLN005 (2.5-20 μM; 24 hours ) activates AMPK in a dose-dependent manner[1]. Western Blot Analysis[1] Cell Line: | ||||||||||||
| In Vivo | ZLN005 (15 mg/kg; p.o.; per day for 4 weeks) decreases random blood glucose and fasting blood glucose levels over 4 weeks compared with lean mice[1]. Animal Model: | ||||||||||||
| Name | ZLN005 | ||||||||||||
| CAS | 49671-76-3 | ||||||||||||
| Formula | C17H18N2 | ||||||||||||
| Molar Mass | 250.34 | ||||||||||||
| Appearance | Solid | ||||||||||||
| Transport | Room temperature in continental US; may vary elsewhere. | ||||||||||||
| Storage |
|
||||||||||||
| Reference | [1]. Zhang LN, et al. Novel small-molecule PGC-1α transcriptional regulator with beneficial effects on diabetic db/db mice. Diabetes. 2013 Apr;62(4):1297-307. |